ArticleEuropean heart journal2025
Atrial amyloidosis identified by biopsy in atrial fibrillation: prevalence and clinical presentation.
Article in European heart journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07567508 (Early Detection of Concealed Cardiac Amyloidosis Using AI-ECG and CT-Derived Extracellular Volume in Patients With Atrial Fibrillation), which is not on this map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Early Detection of Concealed Cardiac Amyloidosis Using AI-ECG and CT-Derived Extracellular Volume in Patients With Atrial Fibrillation
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prevalence of cardiac amyloidosis in screening studies: a systematic review and meta-analysis.ESC heart failure · 2026Pooled it
- Article
- Atrial Cardiomyopathy and Atrial Fibrillation: Insight From Histopathological Analysis of Atrial Biopsies.Korean circulation journal · 2026Review
- Atrial Fibrillation in Infiltrative Cardiomyopathies: From Atrial Cardiomyopathy Imaging to Targeted Management-A Narrative Review.Medicina (Kaunas, Lithuania) · 2026Review
- Clinical Factors Associated With PositiveCirculation reports · 2026Article
- Wild Type Transthyretin Amyloid Cardiomyopathy Hidden Under Ablation-Refractory Atrial Arrhythmias and the Potential Contribution of Tafamidis in Rhythm Control.Journal of arrhythmia · 2026Article
- Triplane Left Atrial Reservoir Strain in Cardiac Amyloidosis: A Comparative Study with Rhythm-Matched Controls.Clinics and practice · 2026Article
- Sex differences in atrial fibrillation-related atrial remodelling assessed by electroanatomic mapping and biopsy.European heart journal · 2026Article
- Yield and predictors of conversion on serial amyloid nuclear SPECT/CT in at-risk populations for transthyretin cardiac amyloidosis.European heart journal. Imaging methods and practice · 2026Article
- Electrocardiographic Features in Transthyretin Cardiac Amyloidosis.Diagnostics (Basel, Switzerland) · 2025Article
- Advances in imaging-based diagnosis, prognosis, and response assessment in cardiac amyloidosis: a comprehensive multimodality review.Annals of nuclear medicine · 2025Review
- Wall Thickness-Guided vs. Voltage-Guided Pulmonary Vein Isolation for Atrial Fibrillation.Journal of arrhythmia · 2025Article
- Feasibility and Safety of Atrial Biopsy - Evidence From 1,000 Cases.Circulation reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
Abstract
BACKGROUND AND
aimsThis study aimed to assess the prevalence of cardiac amyloidosis (CA) in patients with non-valvular atrial fibrillation (AF) and to test the hypothesis that early-stage CA can be identified through atrial biopsy.
methodsAtrial biopsy was performed on 578 patients during AF ablation, with right ventricular (RV) biopsy conducted in 385 patients. The amyloid type was assessed using immunohistochemistry. Patients were classified into groups of atrial biopsy-detected CA (abio-CA) and non-CA, with an additional 58 patients clinically diagnosed with CA comprising the clinical CA group.
resultsAmyloid deposits were identified in atrial samples from 40 patients (7%), including 25 amyloid transthyretin (ATTR) types. Prevalence increased to 20%-40% with advancing age, left ventricular (LV) hypertrophy, and the presence of low-voltage areas in the left atrium. The abio-CA group exhibited a thinner LV posterior wall (11.3 ± 2.2 vs 15.3 ± 4.6 mm, P < .001) compared with the clinical CA group. The abio-CA group displayed a thicker LV posterior wall (11.3 ± 2.2 vs 9.6 ± 1.4 mm, P < .001) and a higher frequency of low-voltage areas defined as <0.5 mV (45% vs 13%, P < .001) compared with the non-CA group. Right ventricular biopsy identified amyloid deposits in 13 patients (3%), comprising 11 ATTR and 2 light-chain types. Among the 26 patients in the abio-CA group who underwent RV biopsy, 13 had no amyloid deposits in RV samples, indicating confined atrial amyloidosis.
conclusionsAtrial biopsy revealed amyloid deposits in 7% of patients undergoing AF ablation, identifying early-stage CA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.